Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRS and ICI Concurrent With NovoTTF-200M in Melanoma Brain Metastases
NCT05341349Phase 1Terminated
- Sponsor
- Emory University
- Start
- Oct 2022
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial in melanoma brain metastases (MBM) (2 arms), sponsored by Emory University. Primary endpoint: Percentage of patients developing grade 3 CNS toxicity at 3 months. Started Oct 2022; status: terminated.
02
Conditions
melanoma brain metastases (MBM)
Beyond the preview
Go deeper on NCT05341349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05341349.